Adjuvant Chemotherapy Following Surgery for Lung Cancer

Kathryn A. Gold

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Surgical resection is the standard treatment for patients with early stage nonsmall cell lung cancer, but after surgical resection alone, disease recurrence is frequently seen. Adjuvant chemotherapy has the potential to improve outcomes by eliminating micrometastatic disease before it can become clinically evident. A number of large clinical trials have been performed to determine the utility of this approach. Early trials did not show a benefit, but more recent randomized studies using cisplatin-based chemotherapy regimens have shown an absolute survival benefit of about 5% at five years. In this chapter, we will review clinical trial data, discuss which patients are good candidates for adjuvant chemotherapy, and address several questions which are currently under active investigation.

Original languageEnglish (US)
Title of host publicationLung Cancer
Subtitle of host publicationFourth Edition
PublisherWiley-Blackwell
Pages278-289
Number of pages12
ISBN (Electronic)9781118468791
ISBN (Print)9781118468746
DOIs
StatePublished - May 27 2014

Keywords

  • Adjuvant treatment
  • Biomarkers
  • Chemotherapy
  • Lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Adjuvant Chemotherapy Following Surgery for Lung Cancer'. Together they form a unique fingerprint.

Cite this